693 related articles for article (PubMed ID: 17512856)
1. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
; Cuzick J; Ambroisine L; Davidson N; Jakesz R; Kaufmann M; Regan M; Sainsbury R
Lancet; 2007 May; 369(9574):1711-23. PubMed ID: 17512856
[TBL] [Abstract][Full Text] [Related]
2. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
3. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Goel S; Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
[TBL] [Abstract][Full Text] [Related]
4. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
[TBL] [Abstract][Full Text] [Related]
5. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
6. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
7. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.
Sverrisdottir A; Johansson H; Johansson U; Bergh J; Rotstein S; Rutqvist L; Fornander T
Breast Cancer Res Treat; 2011 Aug; 128(3):755-63. PubMed ID: 21625929
[TBL] [Abstract][Full Text] [Related]
8. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
[TBL] [Abstract][Full Text] [Related]
10. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer.
Hackshaw A; Baum M; Fornander T; Nordenskjold B; Nicolucci A; Monson K; Forsyth S; Reczko K; Johansson U; Fohlin H; Valentini M; Sainsbury R
J Natl Cancer Inst; 2009 Mar; 101(5):341-9. PubMed ID: 19244174
[TBL] [Abstract][Full Text] [Related]
11. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
12. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
Conte B; Poggio F; Del Mastro L
Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
[TBL] [Abstract][Full Text] [Related]
13. The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women.
Robertson JF; Blamey RW
Eur J Cancer; 2003 May; 39(7):861-9. PubMed ID: 12706354
[TBL] [Abstract][Full Text] [Related]
14. Systematic review of LHRH agonists for the adjuvant treatment of early breast cancer.
Sharma R; Beith J; Hamilton A
Breast; 2005 Jun; 14(3):181-91. PubMed ID: 15927827
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
[TBL] [Abstract][Full Text] [Related]
16. [The use of GnRH analogues in early and advanced breast carcinomas].
Ségura C; Avenin D; Gligorov J; Selle F; Estéso A; Beerblock K; Emile G; Do Huyen N; Lotz JP
Gynecol Obstet Fertil; 2005 Nov; 33(11):914-9. PubMed ID: 16246613
[TBL] [Abstract][Full Text] [Related]
17. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
18. New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients.
Del Mastro L; Rossi G; Lambertini M; Poggio F; Pronzato P
Cancer Treat Rev; 2016 Jan; 42():18-23. PubMed ID: 26613834
[TBL] [Abstract][Full Text] [Related]
19. [LH-RH analogue for the treatment in premenopausal, receptor-positive breast cancer].
Sano M; Makino H
Nihon Rinsho; 2000 Apr; 58 Suppl():328-33. PubMed ID: 11026014
[No Abstract] [Full Text] [Related]
20. Use of goserelin in the treatment of breast cancer.
Rody A; Loibl S; von Minckwitz G; Kaufmann M
Expert Rev Anticancer Ther; 2005 Aug; 5(4):591-604. PubMed ID: 16111461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]